Epizyme Inc.'s (EPZM) first drug TAZVERIK, which was granted accelerated FDA approval for the treatment of metastatic or locally advanced epithelioid sarcoma last month, will face the U.S regulatory agency again in June.
from RTT - Before the Bell https://ift.tt/31VNO8U
via IFTTT
No comments:
Post a Comment